Given that the target of the drug trastuzumab is the HER2 receptor protein, novel detection systems that accurately and quantitatively detect HER2 protein on the membrane of tumor cells in formalin fixed, paraffin embedded (FFPE) clinical samples in a linear fashion over a broad dynamic range would be advantageous, and may provide clinically useful information. Here, ERBB2 is linked to neoplasm.